Conclusions from Munich Round Table on European MedTech Research and Innovation

1. Conclusions from Munich Round Tableon European MedTech Research and Innovation David Simpson General Secretary EAMBES Reader, Biomedical Signal Processing, University of Southampton, UK

2. Munich Round Table 8 June, 2011

3. Introductions • What is MedTech • Technology for disease prevention, screening, diagnosis and for patient monitoring and treatment • Biomedical Engineering • Not biotechnology, genetic engineering, … • Munich Round Table • MedTech EU Net • Technical University of Denmark • Participants from industry, academia, healthcare and civil societies

4. Introductions • Who is EAMBES • European Alliance of Medical and Biological Engineering and Science • Membership: 24 national and 5 trans-national societies26 academic and research institutions; representing some 8000 Biomedical Engineers in Europe • Who am I • General Secretary of EAMBES • Reader in Biomedical Signal Processing,University of Southampton, UKResearch interests in cardiovascular physiology/medicine, physiotherapy and hearing

5. MedTech in Europe • Addressing societal challenges through European Research Cooperation • Challenges: • Ageing population, chronic illness or disability • Healthcare costs • Economic opportunities • MedTech is part of the solution for Europe • Healthcare and quality of life • Economic potential: • €95 billion (2009), 5-7% growth • 8% reinvested in R&D • Job creation: • 500 000 jobs • 80% SMEs

6. Recommendations from Munich Adequate and sustainable funding strategy for research and innovation Big societal challenges have small and medium-sized solutions Adding value by bringing together Fostering an innovation friendly environment Capacity building in neglected areas of research The missing mile in the healthcare innovation cycle

7. 1. Adequate and sustainable funding strategy for research and innovation Short funding cannot achieve full potential Need for sustainable/renewable support over longer periods Need uncomplicated calls in multidisciplinary technologies for medicine/healthcare/life sciences Need appropriate project review processes that recognizes Biomedical Engineering

8. 2. Big societal challenges have small and medium-sized solutions Most novel medical technologies originate in small and medium sized enterprises (SMEs) SMEs are core for MedTech New technologies often go to start-ups, rather than existing companies Need to support start-ups, which often become SMEs.

9. 3. Adding value by bringing together Recommend clusters, with industry, health-care providers and research centres, encouraging public-private partnerships Need to map state-of-the-art in MedTech in Europe, identifying gaps, strengths and opportunities

10. 4. Fostering an innovation friendly environment Price-driven choices often do not consider the entire value chain The right technology in the right place and time is part of the solution Need innovation friendly environment, with early evaluation of innovation, and simpler regulatory frameworks

11. 5. Capacity building in neglected areas of research Currently European MedTech focus is on IT and diagnostics Need to support therapeutic technology research

12. 6. The missing mile in the healthcare innovation cycle Much European research is not well exploited commercially in Europe Often research results show promise in pre-clinical tests, but industrial funding becomes available when clinical benefit / commercial potential is more evident: THE MISSING MILE Need to support technologies further in the development cycle

13. Recommendations Adequate and sustainable funding strategy for research and innovation Big societal challenges have small and medium-sized solutions Adding value by bringing together Fostering an innovation friendly environment Capacity building in neglected areas of research The missing mile in the healthcare innovation cycle